The FDA banned sales of ranitidine in 2020 over possible contamination with the suspected carcinogen N-nitrosodimethylamine (NDMA. Some manufacturers of the drug voluntarily suspended sales in ...

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

Analysts at JPMorgan said this morning there’s a 50 per cent chance of a $5bn (£3.9bn) Zantac liability. Citi analyst Peter Verdult pegged the bill at between $2bn (£1.6bn) and $3bn (£2.4bn).

GSK launched Zantac in 1981 and it was first approved for sale in the US in 1983 as a prescription medication. It went on to become the world's best-selling drug, with annual sales in excess of $1bn.